Joachim Aerts discusses whether the benefits of low-dose computed tomography (#LDCT) can be extended to never-smokers, highlighting data from the Chinese Lung-Care Project presented at #ELCC26. Read more in the #ESMODailyReporter ➡️ https://ow.ly/U5j050YzNuM

📌@mdcurioni.bsky.social discusses the challenges of overcoming acquired resistance to #immunotherapy in #NSCLC, highlighting some positive and negative trial data from #ELCC26. Learn more in the #ESMODailyReporter 👉 https://ow.ly/f7WB50YA1b0

#ELCC26: Optimising #CancerTreatment is essential. In the #ESMODailyReporter,Sanjay Popat highlights strategies to enhance treatment effects, overcome resistance and improve supportive care.
Read the editorial: https://ow.ly/663V50YzMUm

#ELCC26: Improved overall survival was observed with gotistobart, a novel anti-CTLA-4 antibody, versus docetaxel in stage 1 of the PRESERVE-003 trial in patients with squamous #NSCLC who progressed on anti-PD-(L)1 therapy.
#ESMODailyReporter 📌 https://ow.ly/TU2Z50YzKVC

#ELCC26: Non-inferiority for overall survival was demonstrated with late versus early IV #immunotherapy administration in the ETOP-Roche i-TiMES meta-analysis of 8 trials in ##LungCancer. Read more in the #ESMODailyReporter 📌 https://ow.ly/bmty50YzJjT

#ELCC26: Results from ETOP ADEPPT demonstrate the benefits of adagrasib in older patients but caution is needed in patients with poor performance status.
Read more of the latest insights in KRAS G12C-mutated #NSCLC in the #ESMODailyReporter ➡️ https://ow.ly/TXC050YzeZ0

In an Opinion piece in the #ESMODailyReporter, Umberto Malapelle explains how presentations at #ELCC26 have sought to incorporate multimodal insights into early detection, progression prediction and rehabilitation: https://ow.ly/Qu2B50Yz7Ca

Antonio Passaro describes the long-lasting scientific and human legacy of his mentor, Filippo de Marinis, recipient of the #ELCC26 Heine H. Hansen Award, who sadly passed away in February. Read about de Marinis’ contributions in the #ESMODailyReporter 📌https://ow.ly/hpuI50YyAOn

#ESMOTAT26: Semi-autonomous and autonomous agents and domain-specific foundation #AI models are helping transform #CancerResearch and clinical development according to Jorge Reis-Filho. Read the full Opinion piece in the #ESMODailyReporter: https://ow.ly/CQhL50YvHJW

#ESMOTAT26: As discussed by Nina Weisser in the #ESMODailyReporter, multispecifics offer huge potential but there are hurdles to overcome related to engineering, manufacturing, appropriate trial design and avoiding toxicity. Learn more ➡️ dailyreporter.esmo.org/esmo-targete...

#ESMOTAT26: Around half of patients treated with #TargetedTherapies according to ESCAT tier I and tier II survived for at least 12 months in early-phase ClinicalTrials within the 360 RESISTANCE study. Read more in the #ESMODailyReporter 📌 https://ow.ly/jIoQ50YvfMT

Novel agents targeting CD47-SIRPα alone or simultaneously with other mechanisms have the potential to promote antitumour efficacy as suggested by two phase I #ClinicalTrials presented at #ESMOTAT26. Read more details in the #ESMODailyReporter ➡️ https://ow.ly/VCt350YuNrT

#ESMOTAT26: In his interview in the #ESMODailyReporter, Timothy A. Yap, TAT Honorary Awardee, shares insights on innovative approaches to exploit synthetic lethality to ‘drug the undruggable’
📌https://ow.ly/FkSE50YuA7Q

#DrugDevelopment

#ESMOTAT26: Fostering academic #ClinicalResearch is one of the ESMO’s priorities, and #ArtificialIntelligence may be a major driver.
Read the Editorial by @fandremd.bsky.social in the #ESMODailyReporter ➡️ https://ow.ly/JYkz50YuzTr

Some undifferentiated #sarcomas appear to be responsive to #immunotherapy but reliable #biomarkers are needed. @pawelsobczuk.bsky.social
explains more in his Opinion piece in the #ESMODailyReporter ➡️https://ow.ly/Gr0t50YtqJj

#ESMORareCancers26

#ESMORareCancers26: Preliminary data with the DR5 agonist, ozekibart, added to chemotherapy indicate robust activity and a manageable safety profile in relapsed/refractory #EwingSarcoma. Learn more ➡️https://ow.ly/fR7Z50Ytqq5

#ESMODailyReporter

#ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced with safety and fertility considerations. Check out the #ESMODailyReporter: https://ow.ly/8jpy50YsKVz

In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival.
#ESMORareCancers26 #ESMODailyReporter
📌 https://ow.ly/nooJ50YsIQ9

Why are older adults still not properly considered in #ClinicalResearch? In the #ESMODailyReporter, Anna Mislang & Capucine Baldini highlight key barriers and stress the need to integrate #QoL, functional independence and patient priorities in trial design.
➡️ https://ow.ly/vG6J50YmlfO

Unlocking unstructured #EMR data is key to understanding cancer trajectories.
A study in ESMO Real World Data & Digital Oncology shows how #NLP can extract #ClinicalInsights from narrative clinical documentation.
Read Rodrigo Dienstmann in the #ESMODailyReporter
➡️ https://ow.ly/LC2o50YkRYS

Can less mean more? Immunotherapy changed #CancerCare — but access remains unequal. Dose optimisation may help make treatment sustainable and equitable. Equity starts with evidence. #ESMODailyReporter 📌 https://ow.ly/fT1450XZX20

#GenderMedicine ≠ women’s health. Misconceptions persist due to sex & gender data gaps in #ClinicalTrials and poor reporting. Integrating these factors is vital for fair, evidence-based care.
More in the #ESMODailyReporter 📌 https://ow.ly/Ha6P50XX5B0

Radiomics + real-world data improve survival prediction in stage IV #NSCLC on immunotherapy. A study in ESMO Real World Data & Digital Oncology shows ML models outperform PD-L1. Read Rodrigo Dienstmann in the #ESMODailyReporter #HealthAI 🔗 https://ow.ly/hzzj50XVYbH

New prospective data from #ESMOAsia25 show that in MRI-positive #ProstateCancer, TB+iSB is non-inferior to standard TB+SB, potentially streamlining diagnosis and reducing unnecessary biopsy cores.
#ESMODailyReporter 📌 https://ow.ly/5hUa50XTkno

KANDLELIT-001:As presented at #ESMOAsia25, the next-generation KRAS G12C inhibitor MK-1084 continues to show manageable safety and encouraging antitumour activity in advanced #CRC, as monotherapy and in combination regimens.
#ESMODailyReporter 📌 https://ow.ly/hkAI50XTkiQ

ML& DL models can predict DFS and OS after neoadjuvant chemotherapy in HR+/HER2- #BreastCancer using routine data. A study suggests interpretable models may perform well without complex data.

Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh

In the #ESMODailyReporter, Umberto Malapelle explains how concomitant analysis of DNA and RNA can advance cancer characterisation and guide clinical decision making, highlighting data presented at #ESMOAsia25
📌 https://ow.ly/bGI350XM8f6

#PrecisionOncology

Developing guidance in #AI is challenging as technology evolves rapidly. ESMO task forces have developed long-lasting recommendations to support the responsible use of AI in #oncology. Read more in the #ESMODailyReporter 📌 https://ow.ly/XonL50XLkVg

#HealthAI #DigitalOncology

Although the IMbrave152/SKYSCRAPER-14 trial found that adding tiragolumab to 1L atezo + bev did not improve PFS, other studies are under way to evaluate whether additional checkpoint inhibition might still improve outcomes.
#ESMODailyReporter: https://ow.ly/Bfy950XGUCF

#ESMO25

#AI improves pathology precision. A study in ESMO Real World Data & Digital Oncology shows that an AI tool offers reliable PD-L1 scoring, reducing variability & aiding in challenging cases.
Read the commentary @rdienstmann
#ESMODailyReporter #HealthAI https://ow.ly/Ea5G50XHiIG